Product Information
METHOTREXATE 250 MG/10 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $3.2634 per ML under NDC 63323012310. Its NADAC has been published 657 times since Nov 28, 2013.
The High Outlier badge above means this manufacturer's average price in the METHOTREXATE SODIUM market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323012310
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRAVENOUS
Last Updated
6/17/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA040263On Market Since
9/10/2001
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 250 MG/10 ML VIAL has been published 657 times since Nov 28, 2013, and over the history we have for it it has risen 32.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.2634 per ML |
|---|---|
| All-time high | $3.5278 (Jul 15, 2015) |
| All-time low | $2.4714 (Nov 28, 2013) |
| 52-week high | $3.3602 |
| 52-week low | $2.9679 |
| Median price | $3.1986 |
| Average price | $3.1753 |
| Largest weekly change | -20.7% (Jul 17, 2024) |
| Weeks tracked | 657 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the METHOTREXATE SODIUM market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of METHOTREXATE 250 MG/10 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 250 MG/10 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $3.2634 per ML (NDC 63323012310), effective Jun 24, 2026.
How has the price of METHOTREXATE 250 MG/10 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has risen 32.0%. It has been tracked across 657 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 250 MG/10 ML VIAL?
Since Nov 28, 2013, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has ranged from a low of $2.4714 (Nov 28, 2013) to a high of $3.5278 (Jul 15, 2015), with a median of $3.1986 per ML.
Are there cheaper alternatives to METHOTREXATE 250 MG/10 ML VIAL?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of METHOTREXATE 250 MG/10 ML VIAL, so no direct lower-cost alternative is listed.
Who manufactures METHOTREXATE 250 MG/10 ML VIAL?
METHOTREXATE 250 MG/10 ML VIAL (NDC 63323012310) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification